Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

NantKwest (NK) Competitors

NantKwest logo

NK vs. NVAX, VIR, ADPT, REPL, PSTX, DNA, OPT, AVXL, LENZ, and RLAY

Should you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Novavax (NVAX), Vir Biotechnology (VIR), Adaptive Biotechnologies (ADPT), Replimune Group (REPL), Poseida Therapeutics (PSTX), Ginkgo Bioworks (DNA), Opthea (OPT), Anavex Life Sciences (AVXL), LENZ Therapeutics (LENZ), and Relay Therapeutics (RLAY). These companies are all part of the "medical" sector.

NantKwest vs.

Novavax (NASDAQ:NVAX) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk.

Novavax received 577 more outperform votes than NantKwest when rated by MarketBeat users. Likewise, 74.11% of users gave Novavax an outperform vote while only 49.91% of users gave NantKwest an outperform vote.

CompanyUnderperformOutperform
NovavaxOutperform Votes
850
74.11%
Underperform Votes
297
25.89%
NantKwestOutperform Votes
273
49.91%
Underperform Votes
274
50.09%

53.0% of Novavax shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 1.0% of Novavax shares are owned by insiders. Comparatively, 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Novavax presently has a consensus target price of $17.83, indicating a potential upside of 123.20%. Given Novavax's stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than NantKwest.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
NantKwest
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Novavax has a net margin of -32.18% compared to NantKwest's net margin of -76,658.58%. Novavax's return on equity of 0.00% beat NantKwest's return on equity.

Company Net Margins Return on Equity Return on Assets
Novavax-32.18% N/A -17.05%
NantKwest -76,658.58%-56.06%-46.93%

In the previous week, Novavax had 8 more articles in the media than NantKwest. MarketBeat recorded 8 mentions for Novavax and 0 mentions for NantKwest. Novavax's average media sentiment score of 0.51 beat NantKwest's score of 0.00 indicating that Novavax is being referred to more favorably in the media.

Company Overall Sentiment
Novavax Positive
NantKwest Neutral

Novavax has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500.

NantKwest has lower revenue, but higher earnings than Novavax. NantKwest is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$983.71M1.30-$545.06M-$2.26-3.54
NantKwest$40K9,349.00-$65.79M-$0.70-4.89

Summary

Novavax beats NantKwest on 13 of the 18 factors compared between the two stocks.

Get NantKwest News Delivered to You Automatically

Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NK vs. The Competition

MetricNantKwestBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$373.96M$3.11B$5.84B$9.15B
Dividend YieldN/A1.55%4.75%3.85%
P/E Ratio-4.8229.6426.3819.16
Price / Sales9,349.00329.47435.3370.72
Price / CashN/A168.8738.0134.83
Price / Book2.783.687.644.62
Net Income-$65.79M-$71.72M$3.19B$246.06M

NantKwest Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NK
NantKwest
N/A$3.42
-6.0%
N/A-34.7%$373.96M$40,000.00-4.82160Analyst Forecast
High Trading Volume
NVAX
Novavax
3.9661 of 5 stars
$8.19
+0.7%
$17.83
+117.7%
+63.7%$1.31B$983.71M-3.621,543Analyst Revision
News Coverage
VIR
Vir Biotechnology
3.1839 of 5 stars
$9.38
-4.7%
$34.83
+271.4%
-7.1%$1.29B$86.18M-2.39580Insider Trade
ADPT
Adaptive Biotechnologies
3.6376 of 5 stars
$7.68
-2.0%
$7.38
-4.0%
+113.1%$1.16B$177.28M-5.73790Analyst Forecast
Insider Trade
REPL
Replimune Group
4.0661 of 5 stars
$13.12
-5.9%
$19.14
+45.9%
+75.8%$953.73MN/A-4.30210Gap Up
PSTX
Poseida Therapeutics
1.0987 of 5 stars
$9.50
flat
$9.50
N/A$928.85M$150.86M-15.08260
DNA
Ginkgo Bioworks
0.8367 of 5 stars
$13.48
-5.4%
$4.58
-66.1%
N/A$774.66M$251.46M-1.031,218Upcoming Earnings
News Coverage
Gap Up
OPT
Opthea
2.0513 of 5 stars
$5.54
-3.3%
$12.00
+116.6%
+54.0%$755.82M$120,000.000.008Upcoming Earnings
Gap Up
AVXL
Anavex Life Sciences
3.7812 of 5 stars
$8.81
+3.5%
$44.00
+399.4%
+66.7%$747.23MN/A-16.9440Analyst Forecast
Analyst Revision
Gap Up
LENZ
LENZ Therapeutics
1.4696 of 5 stars
$25.00
-1.1%
$35.40
+41.6%
N/A$687.50MN/A0.00110
RLAY
Relay Therapeutics
1.6404 of 5 stars
$4.01
-5.0%
$20.50
+411.2%
-62.9%$671.19M$25.55M-1.54330

Related Companies and Tools


This page (NASDAQ:NK) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners